Methylphenidate in a double-blind crossover trial
Blockmans D et al. · 2006 · American Journal of Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Methylphenidate 10 mg twice daily versus placebo in two four-week crossover periods.
Dose, route and schedule
Methylphenidate 10 mg twice daily versus placebo in two four-week crossover periods.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinically significant response | 10/60 (17%) had a clinically significant fatigue response and 13/60 (22%) a concentration response during methylphenidate. |
Short-term fatigue and concentration scales do not establish sustained benefit or effects on post-exertional malaise.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Short-term fatigue and concentration scales do not establish sustained benefit or effects on post-exertional malaise.
Source access
Methylphenidate 10 mg twice daily versus placebo in two four-week crossover periods.
Source reviewed 2026-11-12.
Citation and original source
Original source: Blockmans D et al.. Methylphenidate in a double-blind crossover trial American Journal of Medicine 2006.
Molekul research summary: https://molekul.io/research/methylphenidate-cfs-2006. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry